Semaglutide Dosing Guide: Maximum Doses & Personalization

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide's maximum approved weekly dose is 2.4 mg for weight management and 2.0 mg for type 2 diabetes. However, optimal dosing varies significantly among individuals based on clinical indication, metabolic factors, and genetic predispositions in GLP-1 receptor and related pathways. Understanding dose ranges helps patients engage meaningfully with providers about personalization.

Dosing is never one-size-fits-all. PlexusDx approaches semaglutide therapy through a precision-wellness lens: genetic variants in GLP1R, GIPR, and metabolic genes may influence how your body responds to escalating doses. This article explores maximum doses, titration protocols, safety thresholds, and how biomarker context can support a more informed conversation with your healthcare provider.

Semaglutide Dose Range by Clinical Indication

Semaglutide dosing depends on whether treatment targets type 2 diabetes or chronic weight management. For diabetes (brand name Ozempic), the maximum is 2.0 mg weekly. For weight management (Wegovy, or compounded formulations), the approved maximum is 2.4 mg weekly. Both follow a titration schedule starting at 0.25 mg.

Titration typically spans 16–20 weeks, increasing every 4 weeks by 0.25 mg increments. This gradual approach allows providers to assess tolerability and efficacy at each level. Not all patients require maximum dose; many achieve clinical goals at 1.0–1.7 mg. Dose decisions balance therapeutic benefit against gastrointestinal side effects and individual response patterns.

Titration Schedule and Dose Escalation Framework

Standard semaglutide titration follows a weekly escalation protocol designed to minimize nausea and vomiting while achieving metabolic targets. This table outlines typical dose progression for weight management and how long providers typically observe each dose before advancing.

Week Range	Dose (mg)	Primary Indication	Expected Duration
Weeks 1–4	0.25	Initiation; GI tolerance assessment	4 weeks
Weeks 5–8	0.5	Efficacy evaluation; side effect monitoring	4 weeks
Weeks 9–12	1.0	Dose stabilization; appetite suppression noted	4 weeks
Weeks 13–16+	1.7–2.4	Maintenance; individualized to response and tolerance	Ongoing

Factors That Influence Individual Dose Requirements

Semaglutide's effect varies based on kidney function, liver health, concurrent medications, prior GLP-1 use, and genetic variation in GLP-1 receptor sensitivity. Patients with renal impairment or hepatic disease may require dose adjustments. Concomitant use of other medications—particularly other diabetes or weight-loss agents—may necessitate slower titration or dose capping.

Genetic variants in the GLP1R gene (rs6923761) and related metabolic pathways influence receptor expression and signaling efficiency. Individuals with certain variants may experience stronger appetite suppression at lower doses, while others may tolerate higher doses with fewer side effects. Provider assessment combined with biomarker context can help tailor escalation decisions for your individual physiology.

Safety Considerations and When Maximum Dose Isn't Necessary

Maximum dose is not a treatment goal; it is an upper limit. Many patients achieve meaningful weight loss or glycemic control at 1.0–1.7 mg weekly and report better tolerability than at higher doses. Gastrointestinal side effects—nausea, vomiting, constipation—increase with dose escalation. Providers may recommend holding at a lower dose if clinical targets are met and tolerability is good.

Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Pregnant individuals should discontinue semaglutide. Severe renal or hepatic impairment may limit dosing. Dehydration risk rises with higher doses due to GI effects. A qualified provider should evaluate your medical history, current medications, and clinical goals before initiating or escalating semaglutide therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines genetic variants including GLP1R rs6923761 and GIPR rs1800437, which influence GLP-1 signaling capacity and appetite-suppression sensitivity. These predispositions may help provide context for why some individuals experience robust appetite suppression at 1.0 mg while others require 1.7–2.4 mg for similar effect. Genetic insights should be interpreted with a qualified healthcare provider as part of a comprehensive dosing strategy.

The test also assesses FTO rs9939609 and MC4R rs17782313, variants linked to metabolic regulation and weight-management responsiveness. Understanding your genetic profile in these pathways does not predict your exact semaglutide response; rather, it can support a more informed baseline conversation about expected dose ranges, side-effect tolerance, and personalized titration pacing. Your provider uses this context alongside clinical observation to optimize your therapy.

Armed with genetic insights, you and your provider can co-create a dosing plan aligned with your physiology, not population averages. This precision approach reduces trial-and-error adjustments and may accelerate identification of your optimal therapeutic dose. PlexusDx compounded semaglutide options ($149/mo) pair seamlessly with personalized dosing strategies guided by genetic and biomarker data.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.